Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Invested Capital (2016 - 2025)

Traws Pharma (TRAW) has disclosed Invested Capital for 14 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 323.56% to $4.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.5 million, a 323.56% increase, with the full-year FY2024 number at -$31.6 million, down 396.38% from a year prior.
  • Invested Capital was $4.5 million for Q3 2025 at Traws Pharma, down from $8.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $49.7 million in Q3 2021 to a low of -$105.5 million in Q2 2024.
  • A 5-year average of $13.7 million and a median of $18.9 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 646.88% in 2021, then tumbled 658.37% in 2024.
  • Traws Pharma's Invested Capital stood at $46.1 million in 2021, then tumbled by 38.62% to $28.3 million in 2022, then tumbled by 62.3% to $10.7 million in 2023, then crashed by 396.38% to -$31.6 million in 2024, then skyrocketed by 114.37% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Invested Capital are $4.5 million (Q3 2025), $8.3 million (Q2 2025), and $6.0 million (Q1 2025).